Full Press Release Details
Alright? All welcome everybody to Wall Street Reporters. Next super
stock live stream where we bring you those stocks which have that 10 x to 100 x upside potential companies going after massive multi-billion
dollar market opportunities that are now at a key inflection point and with multiple catalysts in place for that 10 x. Uh, and that brings
us back to ADTX, uh, and Amro Albanna, the CEO. Amro, welcome back to the program.
Amro Albanna (00:27):
Good to see you again, Jack.
Uh, Amro. So look, the big news is this, again, one of the things that
we look for, one of the things that we want to have with, you know, with our 10 bagger, you know, the key, the, the, the, the system is
we gotta have stocks that are at the inflection point. cause that's where all the money is made. And here's the thing, what's exciting
about Aditxt, the stock fits into, you know, all our criteria that we look for in our, you know, 10 bagger system, which has produced
so many stocks that have gone up 10X, 100x and more. And that one of the big things people need to understand is cheap valuation. You
gotta get in at the ground floor. And it, it doesn't get cheaper than Aditxt. The stock is trading at a, like a $4 million, $3 million
Now the stock is increasing, like literally as we speak, we hit a lull,
there was, I think a capitulation, uh, you know, investors. I think the problem is people don't understand the model and people have kind
of, you know, the stock has been through many cycles. People have given up, they don't understand the model. And that's exactly when the
big money's made. When everybody gives up. And the companies just again, at that inflection point, how do we know, how do we know the
company is at the inflection point? The news flow And the news. The big news, which I think most people missed is, you know, you signed
with, uh, Spartan Capital to, you know, to be the underwriter for the Pearsanta IPO. So Pearsanta, which is one of your three, three,
um, companies that you're building, and we'll talk about your strategy. We're gonna get into the strategy, which am we gotta exploit the
cause I think the market, that's probably why the stock is cheap.
People haven't caught on yet, but I think they will. I think they're gonna catch on. This is the moment. So this marks this, um, the,
the news about, uh, Spartan Capital doing the IPO, which is gonna be a major, if you wanna call it a liquidity event, monetization event,
for Pearsanta. But that totally validates the model. That itself can make the stock a 10 x. I'll explain it my analysis later, but it's
a big deal. So, uh, Amro enough about me talking. Uh, let's, let's, let's,
Amro Albanna (02:35):
I mean, look, let's, let's explain the model. In, in, in very simple
way. It's acquire, build, capitalize, and the innovations we look for, we look for innovations that could address some of our most pressing
health challenges, period. And today since, we're talking about Pearsanta, we're talking about cancer. Everybody understands the significance
of cancer, and we'll talk about it by the numbers. But basically, Aditxt was founded to identify these big innovations with big potential,
build them in-house and capitalize on the opportunity at the right time. Just like what we're doing with, uh, with, with Pearsanta as
And here's, here's the, here's the big thing. Um, by the way, this
is interesting. We have, we have a bunch of people watching, and we just happened, I just saw this comment from Keith. Now Keith, I know
Keith has been follow, I think Keith, or it's another guy, but I think it's Keith, that he's been following our, uh, our channel for probably
five plus years. And he's seen the stocks just like Aditxt. You know, they, they, they came out a little bit early and, you know, people
gave up a little bit too early and then all of a sudden they end up going up 10 x, 20 x and even 50 x. Uh, so again, I think we're, we're
at that stage. Let's, let's explain I first I want for people who don't know, um, let's talk about Pearsanta. What's the, what does the
company do? And then we'll talk about the other parts. We'll go through the business model. But first, again, Pearsanta. What, what, what
does the company do exactly?
Amro Albanna (04:05):
Right? So let's quantify cancer by the numbers, I mean, everybody understands
cancer. Everybody has dealt with it directly or indirectly, but let's talk about it by the numbers. And we will begin by 50% of cancers,
half of cancers are diagnosed too late. Half 70% of cancer death can be prevented. So imagine when we're talking about 10 million people
annually, you know, half of which are diagnosed too late, and 70% of cancer can be prevented by early detection. What that translates
to is $1.2 trillion. Economic opportunity, secondary, of course, to the lives that we're wasting. So nobody can, nobody can, you know,
nobody can disagree with the potential opportunity of addressing cancer via early detection and eventually prevention. But we're starting,
of course, with early detection with prostate cancer, and those are the numbers, when you're talking about 70% more than half can be prevented
with early detection. I think we can all understand and capture the opportunity of what it means to begin going after early detection.
Okay, so let's talk about how does the technology work? I think what's
also very important, I think, which we talked about, I think at an offline a while back, is, um, Spartan Capital's the underwriter that's
gonna be handling the IPO. Uh, I think the banker involved in the deal. He actually was involved with Pearsanta, I think in some capacity.
I think they invested in the stock
Amro Albanna (05:46):
Actually with the original company that we, that we acquired. That's
asset with MDNA biosciences. Okay. Um, yeah, an individual, an individual, not the bank, an individual is actually involved and that's
how we, okay. Okay. Mitochondrial DNA truly is key to understanding our health. And, you know, with, you know, basically we're looking,
we're looking at mitochondrial DNA to detect damage that could tell us whether someone has, uh, early, uh, or, or whether someone has
cancer. But we use mitochondrial as a way to early detect the disease. And that's, and that's the,
Okay, so the technology platform, it's based on, uh, analyzing mitochondrial
Amro Albanna (06:43):
That is correct. And look, you, you can come up with all the innovations
in the world, but if you cannot deploy it, uh, in a logistically feasible manner, economically feasible manner, then it's not gonna matter,
right? With, with, with Pearsantas MDNA platform, we're talking about non-invasive blood tests that basically examines the mitochondrial
DNA of an individual starting with prostate cancer. And the plan here is to move forward with lung cancer, ovarian cancer, breast cancer,
and other types of cancer. But the first commercialization, we're targeting end of this year, Q1 of 2026, starting with prostate cancer.
So we're not years away, we're months away.
Okay. So you, okay, so I guess you answered, uh, I think we answered
a question from, uh, Tomay, which is, okay, this is a blood test analyzing mitochondrial, DNA, uh, and commercialization is starting,
you're saying this year, 2000, uh, 2025,
Amro Albanna (07:49):
The team in Richmond, Virginia, the team in Richmond, Virginia, which
is a CLIA-CAP certified, accredited, uh, laboratory and monitoring center, is working on validation of the first two exams. Actually,
we have prostate cancer as well as endometriosis. Endometriosis is not oncology related. It is, uh, it is for women's health. But we're
starting with these two exams. So Pearsanta really transitions from, you know, uh, you know, promising science, promising innovation to
commercialization. And that is key inflection point for us, Jack, because we acquired an asset, we built it, we set it up, we made it
operationally possible. And the goal here is to launch the first test end of this year, Q1 of 2026, starting again with prostate cancer
endometriosis. That is what Aditxt needs to accomplish. What we need to show that a model is in action, the IPO for Pearsanta is intended
to take, to take, you know, to to, to fully scale the commercialization of Pearsanta beyond prostate and endometriosis and beyond, obviously
the US, Europe, basically take it globally. And that's why 2026 is a very important year for Pearsanta as well as Aditxt.
Okay? So look, the diagnostics market, uh, is, you know, multi-billion
dollar market cancer diagnostics. Again, multi-billion dollar market. Uh, I should have asked ChatGPT what is exactly the size of the,
uh, cancer diagnostics market. So I'm, I'm, I'm, I can't do it now, but if somebody's, if somebody in the audience is watching tell, you
know, ask ChatGPT size of cancer diagnostics market worldwide, I'd like to know. I think it's in, it's in the multi-billions. Um, question
I have for you is, what are, okay, so what are you competing, uh, like what, what are the, um, uh, currently this kind of, the, the, you
know, what, what, what is the market like right now? Like, what is, what are you competing, what will a Pearsanta be competing against
in terms of your technology? Use mitochondrial. DNA. Does anybody else use mitochondrial DNA? How accurate is it? Or what, what are the
benefits compared to other methods? And, you know, what are you competing with and like, pricing wise, so we can understand the kind of
the, your, your competitive advantage that you have over here. So,
Amro Albanna (10:10):
So one scientific competitive advantage using mitochondrial DNA, and
as I mentioned, mitochondrial DNA is truly gonna show that it's key to, to better understand our health. That's number one. Number two,
when you're talking about economically feasible, we're talking about cost that is in sync with existing costs in the market and, and,
you know, easily deployable because we're using existing PCR uh, uh, equipment to actually, to, um, to conduct the test. So we're not
using infrastructure that is proprietary to us. We're using existing industry infrastructure, and that's out of our Richmond, Virginia
laboratory. Um, and again, I mean, look at, look at PSA tests right now for prostate cancer, uh, overtreatment, right? It's unnecessary.
Just because you have high levels does not mean you necessarily have cancer. And that leads to, uh, overtreatment. So just starting with
prostate cancer will begin to show how mitochondrial DNA is more accurate, more precise, uh, logistically and economically very feasible
Okay? So this is a game changer. Okay? Okay. So we just had some audio.
Okay, so by the way, we got, we got, okay, in the audience, we got some, uh, people who, who, okay, so c plus plus one of, uh, one of
our, uh, longtime audience members. He says, cancer diagnostics market today, a hun over 110 billion, closer to 150 to sixty. Let's just,
let's just say a hundred billion dollars. Okay? And this, I say, this is what, Chad, this is from chat GPT, and this is not me saying